Ertumaxomab
Monoclonal antibody
From Wikipedia, the free encyclopedia
Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer.
| Monoclonal antibody | |
|---|---|
| Type | Trifunctional antibody |
| Source | Rat/mouse hybrid |
| Target | HER2/neu, CD3 |
| Clinical data | |
| Trade names | Rexomun |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.[1][2]
Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.[3] (So they could concentrate on their other product catumaxomab (trade name Removab).[4]: 35 )
